Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

被引：0

作者：

Harrison, Simon ^{[1
,2
]}

Riley, Caroline Hasselbalch ^{[3
]}

Manier, Salomon ^{[4
]}

Yoon, Sung-Soo ^{[5
]}

Pinto, Antonio ^{[6
]}

Cazaubiel, Titouan ^{[7
]}

Guidetti, Anna ^{[8
]}

Popat, Rakesh ^{[9
]}

Touzeau, Cyrille ^{[10
]}

Ocio, Enrique ^{[11
]}

Offner, Fritz ^{[12
]}

Rodriguez-Otero, Paula ^{[13
]}

Rizzello, Ilaria ^{[14
,15
]}

Mateos, Maria-Victoria ^{[16
]}

Broeske, Ann-Marie ^{[17
]}

Dekhtiarenko, Iryna ^{[18
]}

Dimier, Natalie ^{[19
]}

Eckmann, Jan ^{[17
,18
]}

Helms, Hans-Joachin ^{[20
]}

Jacob, Wolfgang ^{[17
]}

Schneider, Meike ^{[20
]}

Sleiman, Nassim ^{[20
]}

Weisser, Martin ^{[17
]}

Carlo-Stella, Carmelo ^{[21
,22
]}

机构：

[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Royal Melbourne Hosp, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[3] Rigshospitalet, Copenhagen, Denmark

[4] CHU Lille, Lille, France

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[7] CHU Bordeaux, Bordeaux, France

[8] Ist Nazl Tumori, Milan, Italy

[9] NHS Univ Coll London Hosp, London, England

[10] CHU Nantes, Nantes, France

[11] Marques Valdecilla Univ Hosp, Santander, Spain

[12] Univ Ziekenhuis Gent, Ghent, Belgium

[13] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[14] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedo, Bologna, Italy

[15] Univ Bologna, Bologna, Italy

[16] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[17] Roche Innovat Ctr Munich, Penzberg, Germany

[18] Roche Innovat Ctr Zurich, Zurich, Switzerland

[19] Roche Innovat Ctr Welwyn, Welwyn Garden City, England

[20] Roche Innovat Ctr Basel, Basel, Switzerland

[21] Humanitas Univ, Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy

[22] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-05

引用

页码：S3 / S4

页数：2

共 50 条

[41] Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
Martin, Thomas G.
Moreau, Philippe
Usmani, Saad Zafar
Garfall, Alfred L.
Mateos, Maria-Victoria
San-Miguel, Jesus F.
Rocafiguera, Albert Oriol
Nooka, Ajay K.
Rosinol, Laura
Chari, Ajai
Karlin, Lionel
Krishnan, Amrita Y.
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez, Joaquin
Delforge, Michel
Fastenau, John
Gries, Katharine S.
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.
Minnema, Monique C.
Krishnan, Amrita Y.
Berdeja, Jesus G.
Rocafiguera, Albert Oriol
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Morillo, Daniel
Mateos, Maria-Victoria
Costa, Luciano J.
Caers, Jo
Vishwamitra, Deeksha
Ma, Joanne
Yang, Shiyi
Hilder, Brandi
Tolbert, Jaszianne A.
Goldberg, Jenna D.
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[43] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Bahlis, Nizar J.
Raje, Noopur S.
Costello, Caitlin
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Liu, Feng
Liao, Kai Hsin
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Jakubowiak, Andrzej J.
Chu, Michael P.
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
Touzeau, Cyrille
Krishnan, Amrita Y.
Moreau, Philippe
Perrot, Aurore
Usmani, Saad Zafar
Manier, Salomon
Cavo, Michele
Martinez-Chamorro, Carmen
Nooka, Ajay K.
Martin, Thomas G.
Karlin, Lionel
Leleu, Xavier
Bahlis, Nizar J.
Besemer, Britta
Pei, Lixia
Verona, Raluca
Girgis, Suzette
Uhlar, Clarissa
Kobos, Rachel
Garfall, Alfred L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Zonder, Jeffrey A.
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Sharma, Manish
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Mahdav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
BLOOD, 2021, 138
[46] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Polepally, Akshanth R.
Biesdorf, Carla
Uddin, Muhammad Erfan
Boehm, Nils
Ross, Jeremy A.
Kumar, Shaji Kunnathu
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Bueno, Orlando
Talati, Chetasi
Menon, Rajeev M.
BLOOD, 2023, 142
[47] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, Afshin E.
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos
Viqueira, Andrea
Lesokhin, Alexander M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
[48] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[49] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Ahsan, Aarif
Mantis, Christine
Luo, Xizhi
Zhang, Catherine C.
Valdes, Cesar Rodriguez
Voorhees, Peter M.
D'Souza, Anita
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Mckay, John T.
Weisel, Katja C.
Teipel, Raphael
Korde, Neha
Vij, Ravi
Kumar, Shaji
Bueno, Orlando Felix
Pothacamury, Rajvineeth Kumar
Talati, Chetasi
Ross, Jeremy A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →